FrancophonIA/ELRC3.0 huggingface dataset:
English: The other ingredients are sucrose, poloxamer 188, sodium dihydrogen phosphate monohydrate, disodium phosphate anhydrous, and water for injections (see section 2 "ORENCIA contains sodium").
Croatian: Drugi sastojci su: saharoza, poloksamer 188, natrijev dihidrogenfosfat hidrat, bezvodni natrijev hidrogenfosfat i voda za injekcije (vidjeti dio 2. "ORENCIA sadrži natrij").
English: † p < 0.01, abatacept plus MTX vs. MTX plus placebo ‡ p < 0.001, abatacept plus MTX vs. MTX plus placebo †† p < 0.05, abatacept plus MTX vs. MTX plus placebo § 95% CI: −4.2, 4.8 (based on prespecified margin for non-inferiority of −7.5%) §§ITT data is presented in table a Fixed dose approximating 10 mg/kg (see section 4.2).
Croatian: *** p < 0,001, abatacept naspram placeba. † p < 0,01, abatacept i MTX naspram MTX i placebo ‡ p < 0,001, abatacept i MTX naspram MTX i placebo †† p < 0,05, abatacept i MTX naspram MTX i placebo § 95% CI: −4,2; 4,8 (na temelju prethodno određene granice za neinferiornost od −7,5%) §§U tablici su prikazani podaci za populaciju svih uključenih bolesnika (engl. intend-to-treat, ITT) a Fiksna doza od približno 10 mg/kg (vidjeti dio 4.2).
English: During the extension period of the pJIA studies (20 months in the pJIA SC study and 5 years in the pJIA IV study), the safety profile in the pJIA patients aged 6 to 17 years was comparable to that seen in adult patients.
Croatian: Tijekom razdoblja nastavka ispitivanja primjene kod pJIA-a (20 mjeseci u ispitivanju pJIA SC i 5 godina u ispitivanju pJIA IV) sigurnosni profil u bolesnika s pJIA-om u dobi od 6 do 17 godina starosti bio je usporediv s onim u odraslih bolesnika.
English: It may also be helpful to write down any questions or concerns about the injection so you can ask your doctor, nurse or pharmacist.
Croatian: Ako imate nekih pitanja ili Vas nešto brine u vezi s injekcijom, pomoći će ako to zapišete, tako da možete pitati svog liječnika, medicinsku sestru ili ljekarnika.
English: A randomised and double-blinded study evaluated abatacept SC in combination with methotrexate (abatacept + MTX), abatacept SC monotherapy, or methotrexate monotherapy (MTX group) in induction of remission following 12 months of treatment, and maintenance of drug-free remission after complete drug withdrawal in MTX-naive adult patients with highly active early rheumatoid arthritis with poor prognostic factors.
Croatian: U randomiziranom i dvostruko slijepom ispitivanju ocjenjivali su se abatacept za supkutanu primjenu u kombinaciji s metotreksatom (abatacept + MTX), monoterapija abataceptom za supkutanu primjenu i monoterapija metotreksatom (skupina liječena samo MTX-om) s obzirom na indukciju remisije nakon 12 mjeseci liječenja te održavanje remisije bez liječenja nakon potpunog prekida terapije u odraslih bolesnika s izrazito aktivnim ranim oblikom reumatoidnog artritisa koji prethodno nisu bili liječeni MTX-om i koji su imali loše prognostičke faktore.
English: 0.4 mL pre-filled syringe (type 1 glass) with an automatic needle safety guard and flange extenders (white plunger).
Croatian: 0,4 ml u napunjenoj štrcalji (staklo tipa I) sa s automatskim sigurnosnim štitnikom za iglu i proširenim rubnikom (bijeli klip).
English: A study of open-label intravenous abatacept on a background of nonbiologic DMARDs was conducted in patients with active RA who had an inadequate response to previous (washout for at least 2 months; n=449) or current (no washout period; n=597) TNF-inhibitor therapy (study VII).
Croatian: Ispitivanje otvorene intravenske primjene abatacepta uz osnovnu terapiju nebiološkim DMARD-ima provedeno je u bolesnika s aktivnim reumatoidnim artritisom koji nisu dovoljno dobro odgovorili na prethodnu (faza ispiranja u trajanju od najmanje 2 mjeseca, n=449) ili trenutnu (bez faze ispiranja, n=597) terapiju TNF-inhibitorima (ispitivanje VII).
English: In study SC-I, the goal was to demonstrate non-inferiority of the efficacy and comparability of the safety of abatacept subcutaneous relative to intravenous administration in subjects with moderate to severely active RA and experiencing inadequate response to MTX.
Croatian: U ispitivanju SC-I cilj je bio dokazati neinferiornost u pogledu djelotvornosti te usporedivu sigurnost abatacepta primijenjenog supkutano u odnosu na intravensku primjenu u ispitanika s umjerenim do teškim oblikom aktivnog reumatoidnog artritisa koji nisu dovoljno dobro odgovorili na MTX.
English: They had active disease, with baseline mean active joint count of 16 and a mean number of joints with loss of motion of 16; and elevated C-reactive protein (CRP) levels (mean, 3.2 mg/dl) and ESRs (mean, 32 mm/h).
Croatian: Bolesnici su imali aktivnu bolest te su na početku ispitivanja imali prosječno 16 aktivnih zglobova, 16 zglobova u kojima je pokretljivost bila izgubljena, povišene razine C-reaktivnog proteina (CRP) (prosječna vrijednost 3,2 mg/dl) i povišenu brzinu sedimentacije eritrocita (prosječna vrijednost 32 mm/h).
English: Do not use if the expiry date has passed.
Croatian: NEMOJTE je upotrijebiti ako je istekao rok valjanosti.
English: ORENCIA (abatacept)
Croatian: Supkutana (potkožna) primjena
English: Similar inhibition was observed in both treatment groups up to 24 months (mTSS (mean ± standard deviation [SD] = 0.89 ± 4.13 vs 1.13 ±8.66), erosion score (0.41 ± 2.57 vs 0.41 ±5.04), and JSN score (0.48 ±2.18 vs 0.72 ±3.81)) for the abatacept (n=257) and adalimumab (n=260) groups, respectively.
Croatian: U obje je skupine, onoj koja je primala abatacept (n=257) i onoj koja je primala adalimumab (n=260), primijećena slična inhibicija tijekom 24 mjeseca (mTSS (srednja vrijednost ± standardno odstupanje = 0,89 ± 4,13 naspram 1,13 ± 8,66), ocjena erozije (0,41 ± 2,57 naspram 0,41 ±5,04) i ocjena JSN-a (0,48 ±2,18 naspram 0,72 ±3,81)).
English: 0.7 mL Fill line
Croatian: 0,7 ml Linija punjenja
English: This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodiumfree'.
Croatian: Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po dozi, tj. zanemarive količine natrija.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON FOR PACKS OF 1, 3 AND 4 PRE-FILLED SYRINGES WITH NEEDLE GUARD
Croatian: PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA ZA PAKIRANJA OD 1, 3, I 4 NAPUNJENE ŠTRCALJKE SA ŠTITNIKOM ZA IGLU
English: In study SC-III, similar immunogenicity rates were seen in patients on treatment for the abatacept+MTX, and abatacept monotherapy groups (2.9% (3/103) and 5.0% (5/101), respectively) during the double-blind 12 month period.
Croatian: U ispitivanju SC-III su tijekom dvostruko slijepog 12-mjesečnog razdoblja primijećene slične stope imunogenosti u bolesnika koji su primali abatacept + MTX i onih koji su se liječili monoterapijom abataceptom (2,9% [3/103] naspram 5,0% [5/101]).
English: During the extension period of the pJIA studies (20 months in the pJIA ongoing SC study and 5 years in the pJIA IV study), the safety profile in the pJIA patients aged 6 to 17 years was comparable to that seen in adult patients.
Croatian: Tijekom razdoblja nastavka ispitivanja primjene kod pJIA (20 mjeseci u ispitivanju pJIA SC, koje je još u tijeku, i 5 godina u ispitivanju pJIA IV) sigurnosni profil u bolesnika s pJIA-om u dobi od 6 do 17 godina bio je usporediv s onim u odraslih bolesnika.
English: MRI Synovitis Score
Croatian: MRI rezultat za sinovitis
English: Abdominal pain, diarrhoea, nausea, dyspepsia, mouth ulceration, aphthous stomatitis, vomiting Uncommon Gastritis
Croatian: Poremećaji probavnog sustava često bol u abdomenu, proljev, mučnina, dispepsija, ulceracije u ustima, aftozni stomatitis, povraćanje manje često gastritis
English: In the smaller study PsA-I, the ACR 20 responses with abatacept 10 mg/kg intravenous vs placebo in patients who were TNF inhibitor-naive were 55.6% vs 20.0%, respectively, and in patients who were TNF inhibitorexperienced were 30.8% vs 16.7%, respectively.
Croatian: PsA-I, među bolesnicima koji prethodno nisu bili liječeni TNF-inhibitorima odgovor ACR 20 postiglo je 55,6% bolesnika liječenih abataceptom u intravenskoj dozi od 10 mg/kg i 20,0% onih koji su primali placebo, dok je među bolesnicima prethodno liječenima TNF-inhibitorima isto zabilježeno u 30,8% odnosno 16,7% bolesnika.
English: One hundred and two (67%) of the subjects had received at least 1,080 days (~ 36 months) of abatacept therapy in Period C. All patients had at least 4 months of prior, open-label abatacept treatment in Period A.
Croatian: U Razdoblju C su 102 (67%) ispitanika imala najmanje 1080 dana (~ 36 mjeseci) liječenja abataceptom.
English: Therefore, ORENCIA solution for injection in pre-filled syringe is not recommended for use in this patient population.
Croatian: Stoga se ne preporučuje primjena ORENCIA otopine za injekciju u napunjenoj štrcaljki u ovoj populaciji bolesnika.
English: Abatacepta +DMARDsb n = 256
Croatian: Abatacepta +DMARD-i b n = 256
English: Methotrexate, NSAIDs, corticosteroids, and TNF-inhibitors were not found to influence abatacept clearance.
Croatian: Utvrđeno je da metotreksat, NSAIL-i, kortikosteroidi i TNF-inhibitori ne utječu na klirens abatacepta.
English: In study VI, the efficacy and safety of abatacept were assessed in methotrexate-naive, Rheumatoid Factor (RF) and/or anti-Cyclic Citrullinated Peptide 2 (Anti-CCP2)-positive patients with early, erosive rheumatoid arthritis (≤ 2 years disease duration) who were randomised to receive abatacept plus methotrexate or methotrexate plus placebo.
Croatian: U ispitivanju VI ispitivale su se djelotvornost i sigurnost abatacepta u bolesnika s ranim, erozivnim reumatoidnim artritisom (trajanje bolesti ≤ 2 godine) koji prethodno nisu primali metotreksat, a imali su pozitivan nalaz reumatoidnog faktora (RF) i/ili antitijela na ciklički citrulinirani peptid 2 (anti-CCP2).
English: The Type 1 glass syringe has a coated stopper and fixed stainless steel needle covered with a rigid needle shield.
Croatian: Staklena štrcaljka (staklo tipa 1) ima obložen čep i pričvršćenu iglu od nehrđajućeg čelika prekrivenu tvrdim štitnikom za iglu.
English: Patients who had not achieved at least a 20% improvement from baseline in their swollen and tender joint counts by week 16 escaped to open-label abatacept 125 mg subcutaneous weekly.
Croatian: Bolesnici kojima se početni broj bolnih i otečenih zglobova nije poboljšao za najmanje 20% do 16. tjedna prešli su na otvoreno liječenje abataceptom u supkutanoj dozi od 125 mg tjedno.
English: - After reconstitution the solution should be clear and colourless to pale yellow.
Croatian: - Rekonstituirana otopina mora biti bistra i bezbojna do blijedožuta.
English: Proceed to Step 5
Croatian: Prijeđite na 5. korak
English: Patients should be screened for latent tuberculosis prior to initiating ORENCIA.
Croatian: Prije uvođenja lijeka ORENCIA bolesnike treba testirati na latentnu tuberkulozu.
English: Each pre-filled syringe contains 50 mg of abatacept in 0.4 mL.
Croatian: Jedna napunjena štrcaljka sadrži 50 mg abatacepta u 0,4 ml.
English: Each vial contains 250 mg of abatacept.
Croatian: Jedna bočica sadrži 250 mg abatacepta.
English: In study PsA-II, the proportion of patients who achieved PASI 50 response was 26.7% with abatacept vs. 19.6% with placebo (7.3 [-2.2, 16.7], estimate of difference [95% CI]), and the proportion of patients who achieved PASI 75 response was 16.4% with abatacept vs. 10.1% with placebo (6.4 [-1.3, 14.1], estimate of difference [95% CI]).
Croatian: U ispitivanju PsA-II, udio bolesnika koji su postigli odgovor PASI 50 iznosio je 26,7% uz abatacept i 19,6% uz placebo (7,3 [-2,2; 16,7], procjena razlike [95% CI]), dok je udio bolesnika koji su postigli odgovor PASI 75 iznosio 16,4% uz abatacept odnosno 10,1% uz placebo (6,4 [-1,3; 14,1], procjena razlike [95% CI]).
English: A study of open-label abatacept on a background of nonbiologic DMARDs was conducted in patients with active RA who had an inadequate response to previous (washout for at least 2 months; n=449) or current (no washout period; n=597) TNF-inhibitor therapy (study VII).
Croatian: Ispitivanje otvorene primjene abatacepta uz osnovnu terapiju nebiološkim DMARD-ima provedeno je u bolesnika s aktivnim reumatoidnim artritisom koji nisu dovoljno dobro odgovorili na prethodnu (faza ispiranja u trajanju od najmanje 2 mjeseca, n=449) ili trenutnu (bez faze ispiranja, n=597) terapiju TNF-inhibitorima (ispitivanje VII).
English: Each pre-filled syringe contains 87.5 mg of abatacept in 0.7 mL.
Croatian: Jedna napunjena štrcaljka sadrži 87,5 mg abatacepta u 0,7 ml.
English: The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Croatian: • Periodička izvješća o neškodljivosti (PSUR-evi) Zahtjevi za podnošenje PSUR-evaza ovaj lijek definirani su u referentnom popisu datuma EU (EURD popis) predviđenom člankom 107c stavkom 7.
English: Abatacept was also evaluated in an open-label study in rheumatoid arthritis patients administered the seasonal influenza trivalent virus vaccine.
Croatian: Abatacept je ocijenjen i u otvorenom ispitivanju u bolesnika s reumatoidnim artritisom koji su primili trovalentno virusno cjepivo protiv sezonske gripe.
English: 87.5 mg/0.7 mL Pre-filled Syringe
Croatian: 87,5 mg/0,7 mL Napunjena štrcaljka
English: ORENCIA 125 mg solution for injection in pre-filled syringe Each pre-filled syringe contains 125 mg of abatacept in one mL.
Croatian: ORENCIA 125 mg otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka sadrži 125 mg abatacepta u jednom ml.
English: In placebo-controlled clinical trials, malignancies were reported in 1.2% (31/2,653) of abatacepttreated patients and in 0.9% (14/1,485) of placebo-treated patients.
Croatian: U placebom kontroliranim kliničkim ispitivanjima zloćudne su bolesti prijavljene u 1,2% (31/2653) bolesnika liječenih abataceptom te u 0,9% (14/1485) bolesnika koji su primali placebo.
English: Package leaflet: Information for the patient ORENCIA 50 mg solution for injection in pre-filled syringe ORENCIA 87.5 mg solution for injection in pre-filled syringe ORENCIA 125 mg solution for injection in pre-filled syringe abatacept
Croatian: Uputa o lijeku: Informacije za bolesnika ORENCIA 50 mg otopina za injekciju u napunjenoj štrcaljki ORENCIA 87,5 mg otopina za injekciju u napunjenoj štrcaljki ORENCIA 125 mg otopina za injekciju u napunjenoj štrcaljki abatacept
English: In study PsA-I, 170 patients received placebo or abatacept intravenously on day 1, 15, 29, and then every 28 days thereafter in a double blind manner for 24 weeks, followed by open-label abatacept 10 mg/kg intravenous every 28 days.
Croatian: U ispitivanju PsA-I, 170 bolesnika primalo je intravenski placebo ili abatacept 1., 15. i 29. dana te svakih 28 dana nakon toga na dvostruko slijep način tijekom 24 tjedna, nakon čega je uslijedila otvorena primjena abatacepta u dozi od 10 mg/kg intravenski svakih 28 dana.
English: ORENCIA SC should be administered weekly at a dose of 125 mg by subcutaneous injection regardless of weight (see section 5.1).
Croatian: ORENCIA za supkutanu primjenu primjenjuje se supkutanom injekcijom u dozi od 125 mg jedanput na tjedan, neovisno o tjelesnoj težini (vidjeti dio 5.1).
English: In study VI, statistically significant improvement in the ACR 20 response in abatacept plus methotrexate-treated patients versus methotrexate plus placebo-treated patients was observed at 29 days, and was maintained through the duration of the study.
Croatian: U ispitivanju VI je tijekom 29 dana opaženo statistički značajno poboljšanje odgovora ACR20 u bolesnika koji su primali abatacept i metotreksat u odnosu na bolesnike koji su primali placebo, i to je poboljšanje ostalo značajno tijekom cjelokupnog trajanja ispitivanja.
English: Do not use prolonged or vigorous agitation.
Croatian: Nemojte je dugotrajno i žustro mućkati.
English: One mL pre-filled syringe (type 1 glass) with flange extenders or one mL pre-filled syringe with an automatic needle safety guard and flange extenders (orange plunger).
Croatian: Napunjena štrcaljka volumena 1 ml (staklo tipa 1) s proširenim rubnikom ili napunjena štrcaljka volumena 1 ml s automatskim sigurnosnim štitnikom za iglu i proširenim rubnikom (narančasti klip).
English: A randomised, double-blind study was conducted to assess the safety and efficacy of abatacept or infliximab versus placebo in patients with an inadequate response to methotrexate (study V).
Croatian: Provedeno je randomizirano, dvostruko slijepo ispitivanje sigurnosti i djelotvornosti abatacepta ili infliksimaba naspram placeba u bolesnika koji nisu dovoljno dobro odgovorili na metotreksat (ispitivanje V).
English: The frequency of local injection site reactions was 3.8% (12/318) and 9.1% (30/328) at 12 months (p=0.006) and 4.1% (13/318) and 10.4% (34/328) at 24 months for abatacept SC and adalimumab SC, respectively.
Croatian: Učestalost lokalnih reakcija na mjestu injekcije iznosila je 3,8% (12/318) u skupini liječenoj abataceptom za supkutanu primjenu i 9,1% (30/328) u skupini liječenoj adalimumabom za supkutanu primjenu nakon 12 mjeseci (p=0,006), a 4,1% (13/318) odnosno 10,4% (34/328) nakon 24 mjeseca.
English: Study SC-II investigated the relative efficacy and safety of abatacept and adalimumab, both given subcutaneously without an intravenous loading dose and with background MTX, in patients with moderate to severely active RA and an inadequate response to previous MTX therapy.
Croatian: U ispitivanju SC-II ispitivale su se relativna djelotvornost i sigurnost abatacepta i adalimumaba u bolesnika s umjerenim do teškim oblikom aktivnog RA koji nisu dovoljno dobro odgovorili na prethodnu terapiju MTX-om; oba su se lijeka primjenjivala supkutano bez intravenske udarne doze, uz osnovnu terapiju MTX-om.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION ORENCIA 87.5 mg injection abatacept
Croatian: NAZIV LIJEKA I PUT(EVI) PRIMJENE LIJEKA ORENCIA 87,5 mg injekcija abatacept s.c.
English: Patients in the sub-study (n=117) of the open-label extension of study SC-I received 125 mg of subcutaneous abatacept administered weekly via the pre-filled syringe for at least 4 months, and were then switched to receive 125 mg SC abatacept administered weekly via the pre-filled pen for 12 weeks.
Croatian: Bolesnici koji su sudjelovali u podispitivanju (n=117) otvorenog produžetka ispitivanja SC-I primali su abatacept za supkutanu primjenu u dozi od 125 mg jedanput na tjedan napunjenom štrcaljkom tijekom najmanje 4 mjeseca.
English: Improvement in physical function was measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) in studies II, III, IV, V, and VI and the modified HAQ-DI in study I. The results from studies II, III, and VI are shown in Table 7.
Croatian: Poboljšanje fizičke funkcije se u ispitivanjima II, III, IV, V i VI mjerilo indeksom nesposobnosti Upitnika za procjenu zdravlja (engl.
English: Treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of rheumatoid arthritis or pJIA.
Croatian: Liječenje mora započeti i nadzirati liječnik specijalist s iskustvom u dijagnosticiranju i liječenju reumatoidnog artritisa odnosno poliartikularnog juvenilnog idiopatskog artritisa.
English: Age and gender (when corrected for body weight) did not affect clearance.
Croatian: Dob i spol (korigirani za tjelesnu težinu) nisu utjecali na klirens.
English: ORENCIA Patient Alert Card
Croatian: ORENCIA kartica s upozorenjima za bolesnika
English: The rate of seropositivity while patients were receiving abatacept therapy was 0.5% (1/189) during Period A; 13.0% (7/54) during Period B; and 12.8% (19/148) during Period C. For patients in Period B who were randomised to placebo (therefore withdrawn from therapy for up to 6 months) the rate of seropositivity was 40.7% (22/54).
Croatian: Udio seropozitivnosti za vrijeme liječenja abataceptom iznosio je 0,5% (1/189) tijekom Razdoblja A, 13,0% (7/54) tijekom Razdoblja B te 12,8% (19/148) tijekom Razdoblja C.
English: Abatacept/methotrexate reduced the rate of progression of structural damage compared to placebo/methotrexate after 12 months of treatment as shown in Table 4.
Croatian: Abatacept i metotreksat su nakon 12 mjeseci liječenja smanjili brzinu napredovanja strukturnog oštećenja u usporedbi s primjenom placeba i metotreksata, kako je prikazano u Tablici
English: Packs of 4 pre-filled syringes with needle guard.
Croatian: Pakiranja od 4 napunjene štrcaljke sa štitnikom za iglu.
English: Needle Cover (cap)
Croatian: Poklopac igle (zatvarač)
English: In study PsA-II, the proportion of radiographic non-progressors (≤ 0 change from baseline) in total PsA-modified SHS on x-rays at Week 24 was greater with abatacept 125 mg subcutaneous (42.7%) than placebo (32.7%) (10.0 [1.0, 19.1] estimate of difference [95% CI]).
Croatian: U ispitivanju PsA-II, udio bolesnika bez radiografske progresije (promjena ≤ 0 u odnosu na početak ispitivanja) prema ukupnom Sharpovom/van der Heijdeovom rezultatu (SHS) prilagođenom za PsA na rendgenskim snimkama u 24. tjednu bio je veći u skupini liječenoj abataceptom u supkutanoj dozi od 125 mg (42,7%) nego u onoj koja je primala placebo (32,7%) (10,0 [1,0; 19,1] procjena razlike [95% CI]).
English: Immunogenicity in adults treated with intravenous abatacept
Croatian: Imunogenost u odraslih bolesnika liječenih abataceptom primijenjenim intravenski
English: No mutagenicity or clastogenicity was observed with abatacept in a battery of in vitro studies.
Croatian: U nizu in vitro ispitivanja nije opaženo mutageno ni klastogeno djelovanje abatacepta.
English: A reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate.
Croatian: Tijekom kombiniranog liječenja abataceptom i metotreksatom pokazana je redukcija progresije oštećenja zglobova i poboljšanje fizičke funkcije.
English: ORENCIA is used to treat rheumatoid arthritis and psoriatic arthritis in adults and also polyarticular juvenile idiopathic arthritis in children 6 years of age and older.
Croatian: ORENCIA se primjenjuje za liječenje reumatoidnog artritisa i psorijatičnog artritisa u odraslih osoba te poliartikularnog juvenilnog idiopatskog artritisa u djece u dobi od 6 ili više godina.
English: ORENCIA is used to treat rheumatoid arthritis and psoriatic arthritis in adults and also polyarticular juvenile idiopathic arthritis in children 2 years of age and older.
Croatian: ORENCIA se primjenjuje za liječenje reumatoidnog artritisa i psorijatičnog artritisa u odraslih osoba te poliartikularnog juvenilnog idiopatskog artritisa u djece u dobi od 2 ili više godina.
English: Age and gender (when corrected for body weight) did not affect apparent clearance.
Croatian: Dob i spol (korigirani za tjelesnu težinu) nisu utjecali na prividni klirens.
English: It should be clear and colourless to pale yellow.
Croatian: Mora biti bistra i bezbojna do blijedožuta.
English: ACR Pedi 30 responders at the end of Period A were randomised into Period B, the double-blind, withdrawal phase, to receive either abatacept or placebo for 6 months or until JIA flare.
Croatian: A randomizirani su u Razdoblje B, dvostruko slijepu fazu ustezanja, tako da su primali ili abatacept ili placebo tijekom 6 mjeseci ili do razbuktavanja JIA-a.
English: *Note: the figure shows the 50 mg pre-filled syringe Proceed to Step 3
Croatian: *Napomena: na slici je prikazana napunjena štrcaljka od 50 mg
English: ORENCIA SC should be administered weekly at a dose of 125 mg abatacept by subcutaneous injection regardless of weight (see section 5.1).
Croatian: ORENCIA za supkutanu primjenu primjenjuje se supkutanom injekcijom u dozi od 125 mg abatacepta jedanput na tjedan, neovisno o tjelesnoj težini (vidjeti dio 5.1).
English: Improve your physical function and your ability to do normal daily activities.
Croatian: ublažavanje znakova i simptoma bolesti usporavanje oštećenja kostiju i zglobova poboljšanje fizičke funkcije i sposobnosti obavljanja uobičajenih svakodnevnih aktivnosti.